<DOC>
	<DOC>NCT01227603</DOC>
	<brief_summary>Randomized, open label, single dose, 4-way crossover study to investigate the bioequivalence of a new fixed dose combination tablet of nifedipine GITS and candesartan with the corresponding loose combination and to compare it with the individual drugs</brief_summary>
	<brief_title>Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Healthy male subject Age: 18 to 45 years (inclusive) at the first screening / examination visit Ethnicity: Caucasian Body mass index (BMI): &gt;/=18 and &lt;/=29,9 kg/mÂ² Systolic blood pressure below 120 or above 145 mmHg Diastolic blood pressure above 95 mmHg Heart rate below 45 or above 95 beats / min Clinically relevant findings in the physical examination Suspicion of drug or alcohol abuse Regular daily consumption of more than 1 L of xanthincontaining beverages Intake of foods or beverages containing grapefruit within 4 weeks before the prestudy examination</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Nifedipine</keyword>
	<keyword>Candesartan</keyword>
	<keyword>FDC</keyword>
</DOC>